Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of fuzuloparib + apatinib + camrelizumab in recurrent platinum-resistant ovarian cancer
ChiCTR1900027114Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib, Rivoceranib and camrelizumab in ovarian cancer, sponsored by Chinese PLA General Hospital. Primary endpoint: Objective response rate. Started Jun 2020; status: recruiting.
02
Drugs
fluzoparibRivoceranibcamrelizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR1900027114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027114.